Skip to main content

European Bare Metal Stent Manufacturers Face Stiff Competition From New Technology


European Bare Metal Stent Manufacturers Face Stiff Competition From New Technology


According to a new report by iData Research, despite the progress in bare metal stent design, in-stent restenosis remains high. For this reason, new technological innovations, such as drug-eluting stents, are being developed and commercialized.

February 12, 2015 09:01 ET Source: iData Research, Inc.

VANCOUVER, BC, Feb. 12, 2015 (GLOBE NEWSWIRE) -- via PRWEB - February 12, 2015 – Vancouver, BC – According to a new report published by iData Research, demand for bare-metal stents in Europe could decline dramatically if competing technologies, such as drug-eluting stents and drug-coated balloons provide cost-effective reductions in restenosis. Restenosis is the re-narrowing of treated blood vessel causing obstructions and decreased blood flow to vital organs. The restenosis rate following the use of bare-metal stents remains high, with re-occlusion occurring in up to 50% of cases.

"The European market for bare-metal stents is showing increasing signs of saturation, with intense competition leading to steep ASP declines," explains Dr. Kamran Zamanian, CEO of iData. "This trend has led the major companies in the field to pursue the commercialization of drug-eluting technology, including balloons and stents, which serve as a substitute for bare-metal stents."

Bare metal stents represent the largest peripheral stent segment in Europe, valued at over €166 million. By 2020, the bare metal stent market in Europe will represent slightly above 72% of the total peripheral stent market.

Other key findings from the latest edition of the iData Research report entitled European Markets for Peripheral Vascular Devices:

Clinical Trials 
Clinical trials continue to play a central role in proving the efficacy of a particular treatment method and the superiority of a particular product. Recent clinical trials have supported the use of covered and drug-eluting stents. These results, and the release of longer-term data, will continue to drive demand for these products whose efficacy is established.

Price Erosion 
Bare metal stents are increasingly perceived as commodities by purchasers. Current generation devices have all shown comparable results in achieving patency. As a result, prices continue to decrease significantly as companies attempt to increase market share. This trend will intensify as lower cost competing devices, such as drug-coated balloons, continue to be used in more procedures.

Back to Top